In this spotlight, we present data from our initial growth and efficacy studies with the E0771 model. The data presented here provides an overview of the E0771 cell line?s response to immuno-oncology agents and radiation therapy to enable design of rational combination studies.

As a result of the engineered T cell binding to the tumor cell, the T cell becomes activated and kills tumor cells in an MHC unrestricted manor.  Mice in preclinical research studies are followed for a number of predefined parameters, evaluating tumor growth and burden to determine the efficacy of the CAR T cells (

Colorectal cancer (CRC) is a major contributor to the whole of cancer as a disease, representing 10% of all cases of cancer; over one million new cases of CRC were observed worldwide in 2018 resulting in over half a million deaths¹.

The American Cancer Society's estimates for melanoma in the United States for 2021 are about 106,110 new melanomas to be diagnosed (about 62,260 in men and 43,850 in women) and about 7,180 people are expected to die of melanoma (about 4,600 men and 2,580 women).

C1498 is a murine AML cell line that arose spontaneously in a C57BL/6 mouse and grows aggressively in syngeneic mice. Our C1498 line has been luciferase- and mCherry-enabled to permit monitoring of whole body tumor growth by bioluminescence imaging (BLI) and quantification of tumor burden in isolated tissues by flow cytometry, respectively.

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC).

Introduction

The BT-474 cell line has a long history, but many of us thought it had run its natural course and was quickly becoming obsolete.

BLI offers a robust, sensitive and high throughput alternative relative to more traditional imaging and biodistribution studies using terminal endpoints, invasive procedures or radiolabeling. We were the first CRO to offer BLI in 2003 and in the 17 years since we have amassed considerable experience and know-how in this optical imaging field.

The panel addresses the growing need to understand how immunotherapy modulates pro-tumor and anti-tumor activity in the myeloid compartment of the tumor microenvironment. In this Tech Spotlight, we demonstrate the power of this 18-color panel that provides a deep dive into myeloid subset immunophenotyping and functional characterization.

Researchers are using preclinical mouse modeling in an effort to employ conventional treatment methods for lymphoma, such as radiotherapy and chemotherapy, in combination with immunomodulatory agents to more effectively treat this disease.